Nautilus Biotechnology Announces Board and Executive Changes

Ticker: NAUT · Form: 8-K · Filed: Jan 31, 2025 · CIK: 1808805

Nautilus Biotechnology, INC. 8-K Filing Summary
FieldDetail
CompanyNautilus Biotechnology, INC. (NAUT)
Form Type8-K
Filed DateJan 31, 2025
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-of-directors, executive-compensation

TL;DR

Nautilus Biotech shakes up board and exec pay. Big changes coming?

AI Summary

Nautilus Biotechnology, Inc. announced on January 27, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its key executives.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.

Risk Assessment

Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and leadership stability.

Key Numbers

Key Players & Entities

FAQ

Who are the specific officers or directors that have departed from Nautilus Biotechnology, Inc.?

The filing indicates the departure of 'Directors or Certain Officers' but does not name the specific individuals in the provided text.

Who are the newly elected directors?

The filing states the election of directors but does not provide their names in the provided text.

What specific changes were made to the compensatory arrangements of certain officers?

The filing mentions 'Compensatory Arrangements of Certain Officers' as an item being reported, but the details of these arrangements are not specified in the provided text.

What is the exact date of the reported changes?

The date of the earliest event reported is January 27, 2025.

What was Nautilus Biotechnology, Inc.'s former company name?

Nautilus Biotechnology, Inc.'s former company name was ARYA Sciences Acquisition Corp III.

Filing Stats: 461 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-01-31 17:15:22

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 31, 2025 NAUTILUS BIOTECHNOLOGY, INC. By: /s/ Sujal Patel Name: Sujal Patel Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing